We use cookies to ensure that we give you the best experience on our website Learn more

Feb 18, 2019

12th International Conference on Advanced Technologies & Treatments for Diabetes

01 - SMALL DOSES OF DASIGLUCAGON CONSISTENTLY INCREASE PLASMA GLUCOSE (PG) LEVELS FROM HYPOGLYCEMIA AND EUGLYCEMIA IN PEOPLE WITH TYPE 1 DIABETES MELLITUS (T1DM)

;

hypoglycemia

glucagon

diabetes mellitus

dual-hormone artificial pancreas system

euglycemia

Abstract

Abstract

thumbnail

Keywords

hypoglycemia

glucagon

diabetes mellitus

dual-hormone artificial pancreas system

euglycemia

Abstract

SMALL DOSES OF DASIGLUCAGON CONSISTENTLY INCREASE PLASMA GLUCOSE (PG) LEVELS FROM HYPOGLYCEMIA AND EUGLYCEMIA IN PEOPLE WITH TYPE 1 DIABETES MELLITUS (T1DM) Ulrike Hövelmann1, Minna Braendholt Olsen2, Ulrik Mouritzen2, Daniela Lamers1, Birgit Kronshage1, Tim Heise1 1Profil, Neuss, Germany 2Zealand Pharma A/S, Glostrup, Denmark Background and Aims: Currently available glucagon formulations are of limited stability, which hinders their use in dual-hormone artificial pancreas (DHAP) systems to prevent hypoglycemia. We characterized the pharmacokinetic and pharmacodynamic properties of dasiglucagon, a novel, stable and liquid formulated glucagon analog and promising candidate for use in DHAP systems. Method: In this randomized double-blind trial 17 patients with T1DM received four single subcutaneous doses (0.03, 0.08, 0.2 and 0.6 mg) of dasiglucagon (4 mg/ml formulation) under hypoglycemic (PG 56-66 mg/dL) or euglycemic (PG 100 mg/dL) conditions. For comparison, three doses (0.03, 0.08 and 0.2 mg) of a commercial glucagon (Glucagon, Eli Lilly) were investigated at euglycemia. Result: Dasiglucagon showed dose-dependent and rapid PG-increases across all doses (mean increase 30 min post-dosing 24-94 mg/dl from hypoglycemia and 39-80 mg/dL from euglycemia, compared to 30-71 mg/dl with Glucagon) (figure). Median time to increase in PG by >20 mg/dL was less than 20 min (18-19.5 min) with 0.03 mg dasiglucagon and 9-15 min with higher doses (Glucagon 13-14 min). In hypoglycemia, 0.03 and 0.08 mg dasiglucagon re-established normoglycemia (PG ≥70 mg/dL) within median times of 14 and 10 min, respectively. All patients achieved a PG ≥70 mg/dL within 30 minutes post-dose at dose levels of 0.08 mg and above. Conclusion: Dasiglucagon rapidly and effectively increases PG even in low doses and in a titratable and dose-dependent fashion from both hypoglycemia and euglycemia. The PD profile described supports dasiglucagon as a promising candidate for use in dual-hormonal closed-loop AP systems.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.